Literature DB >> 25680281

Suprapapillary versus transpapillary stent placement for malignant biliary obstruction: which is better?

Jeong-Hyun Jo1, Byeong-Ho Park2.   

Abstract

PURPOSE: To compare the complications, stent patency, and patient survival with self-expandable metal stents (SEMSs) placed above or across the sphincter of Oddi in malignant biliary obstruction.
MATERIALS AND METHODS: From January 2008 to December 2012, 155 patients were treated with percutaneous transhepatic SEMS placement. Seventy-four patients underwent suprapapillary stent placement (group A), and 81 patients underwent transpapillary stent placement (group B). Complications rates, stent patency, and patient survival were evaluated and analyzed for potential predictors.
RESULTS: In group A, 68 covered and 28 uncovered SEMSs were placed, and, in group B, 78 covered and 19 uncovered SEMSs were placed. Thirty-six stent-related early complications were observed in a total of 154 patients (23.4%): pancreatitis (n = 23), cholangitis (n = 12), and cholecystitis (n = 1). The early complication rates for groups A and B were 14.9% (11 of 74) and 31.3% (25 of 80), respectively (P = .016). Pancreatitis occurred in three patients (4.1%) in group A and 20 patients (25.0%) in group B (P = .001). Stent location was a single independent predictor of pancreatitis (P < .001). Stent occlusions by tumor growth was more frequently observed in group A than in group B (P = .007), whereas stent occlusion by sludge incrustation was more frequently found in group B than in group A (P = .007). There was no significant difference in cumulative stent patency (P = .401) or patient survival (P = .792) between groups.
CONCLUSIONS: To decrease the incidence of pancreatitis, suprapapillary placement of SEMSs is recommended for malignant biliary obstruction, but not in the lower 2 cm of the common bile duct.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25680281     DOI: 10.1016/j.jvir.2014.11.043

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  8 in total

Review 1.  Management of Malignant Biliary Obstruction.

Authors:  Jonathan M Lorenz
Journal:  Semin Intervent Radiol       Date:  2016-12       Impact factor: 1.513

2.  Percutaneous transpapillary biliary stent placement for distal malignant biliary obstruction: Outcomes and survival analysis.

Authors:  Qing-Quan Zu; Jin-Xing Zhang; Bin Wang; Wei Ye; Sheng Liu; Hai-Bin Shi
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

Review 3.  Treatment of Malignant Bile Duct Obstruction: What the Interventional Radiologist Needs to Know.

Authors:  Juan C Camacho; Lynn A Brody; Anne M Covey
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

Review 4.  Palliative Percutaneous Biliary Interventions in Malignant High Bile Duct Obstruction.

Authors:  Amy R Deipolyi; Anne M Covey
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

5.  Comparison of the Clinical Outcomes of Suprapapillary and Transpapillary Stent Insertion in Unresectable Cholangiocarcinoma with Biliary Obstruction.

Authors:  Jongbeom Shin; Jin-Seok Park; Seok Jeong; Don Haeng Lee
Journal:  Dig Dis Sci       Date:  2019-10-04       Impact factor: 3.199

Review 6.  Malignant Biliary Obstruction: Evidence for Best Practice.

Authors:  Leonardo Zorrón Cheng Tao Pu; Rajvinder Singh; Cheong Kuan Loong; Eduardo Guimarães Hourneaux de Moura
Journal:  Gastroenterol Res Pract       Date:  2016-02-11       Impact factor: 2.260

7.  Management of distal malignant biliary obstruction.

Authors:  Emad S Aljahdli
Journal:  Saudi J Gastroenterol       Date:  2018 Mar-Apr       Impact factor: 2.485

8.  Differences in efficacy of uncovered self-expandable metal stent in relation to placement in the management of malignant distal biliary obstruction.

Authors:  Jin-Xing Zhang; Qing-Quan Zu; Sheng Liu; Chun-Gao Zhou; Jin-Guo Xia; Hai-Bin Shi
Journal:  Saudi J Gastroenterol       Date:  2018 Mar-Apr       Impact factor: 2.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.